SCHEMBL1676232

SCHEMBL1676232

O=C(O)c1ccc(Cn2cc(-c3ccc(Cl)cc3Cl)nc2C=Cc2ccc(-c3cc(C(F)(F)F)ccc3F)cc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.41
PTGES O14684 2/20 0.41
ALOX5 P09917 2/20 0.41
KDM4E B2RXH2 1/20 0.41
NPC1 O15118 1/20 0.41
CRHBP P24387 1/20 0.41
CRHR2 Q13324 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ENPP2 Q13822 1/20 0.40
SRD5A2 P31213 1/20 0.38
MEN1 O00255 1/20 0.38
LMNA P02545 1/20 0.38
POLB P06746 1/20 0.38
HPGD P15428 1/20 0.38
KMT2A Q03164 1/20 0.38
ATM Q13315 1/20 0.38
PTGER4 P35408 3/20 0.36
PTGDR Q13258 2/20 0.36
EGLN1 Q9GZT9 1/20 0.36
EGFR P00533 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1676230 1.00 RAB9A (0.41) RAB9APTGESALOX5KDM4ENPC1
SCHEMBL1481287 0.93 RAB9A (0.44) RAB9APTGESALOX5KDM4ENPC1
SCHEMBL1481289 0.93 RAB9A (0.44) RAB9APTGESALOX5KDM4ENPC1
SCHEMBL1676418 0.91 DRD2 (0.43) PTGESALOX5KDM4ESMN1; SMN2POLB
SCHEMBL1676420 0.91 DRD2 (0.43) PTGESALOX5KDM4ESMN1; SMN2POLB
SCHEMBL1481125 0.89 MEN1 (0.42) RAB9APTGESALOX5KDM4ENPC1
SCHEMBL1481124 0.89 MEN1 (0.42) RAB9APTGESALOX5KDM4ENPC1
SCHEMBL1676385 0.87 KDM4E (0.45) RAB9AKDM4ENPC1CRHBPCRHR2
SCHEMBL1676383 0.87 KDM4E (0.45) RAB9AKDM4ENPC1CRHBPCRHR2
SCHEMBL1676281 0.86 KDM4E (0.44) RAB9AKDM4ENPC1CRHBPCRHR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110092553-A1 Substituted Azole Derivatives, Compositions, and Methods of Use TRANSTECH PHARMA, INC. (US) 2011-04-21 US disclosed
EP-1730118-A1 SUBSTITUTED AZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE Transtech Pharma, Inc. (US) 2006-12-13 EP disclosed
WO-2005080346-A1 SUBSTITUTED AZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE TRANSTECH PHARMA, INC. (US) 2005-09-01 WO disclosed
US-20050187277-A1 Substituted azole derivatives, compositions, and methods of use TRANSTECH PHARMA, INC. 2005-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110092553-A1 Substituted Azole Derivatives, Compositions, and Methods of Use PTPRO, PTPN5, PTPRE RAB9A 3396/4885PTGES 1938/4885ALOX5 1066/4885
US-20050187277-A1 Substituted azole derivatives, compositions, and methods of use PTPRO, PTPN5, PTPRE RAB9A 3396/4885PTGES 1938/4885ALOX5 1066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.